Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer.

[1]  M. Ratain,et al.  Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy. , 2018, European urology focus.

[2]  Jeong Hwan Park,et al.  Intrafocal heterogeneity of ERG protein expression and gene fusion pattern in prostate cancer , 2017, The Prostate.

[3]  T. H. van der Kwast,et al.  Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. , 2017, European urology.

[4]  P. Sooriakumaran,et al.  Tumour heterogeneity poses a significant challenge to cancer biomarker research , 2017, British Journal of Cancer.

[5]  Faraz Hach,et al.  Spatial genomic heterogeneity within localized, multifocal prostate cancer , 2015, Nature Genetics.

[6]  Igor Jurisica,et al.  Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. , 2014, The Lancet. Oncology.

[7]  D. Watson,et al.  Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies , 2013, BMC Genomics.

[8]  Anirban P. Mitra,et al.  Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy , 2013, PloS one.

[9]  L. Kestin,et al.  Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Alan W Partin,et al.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.